Molbio Diagnostics Ltd vs Syngene International Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of Molbio Diagnostics Ltd is ₹ 1237 as of 23 Oct 15:30 . The P/E Ratio of Molbio Diagnostics Ltd changed from 0 on March 2021 to 0 on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe P/E Ratio of Syngene International Ltd changed from 53.7 on March 2021 to 49.7 on March 2026 . This represents a CAGR of -1.28% over 6 years The Market Cap of Molbio Diagnostics Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Market Cap of Syngene International Ltd changed from ₹ 21734 crore on March 2021 to ₹ 15724 crore on March 2026 . This represents a CAGR of -5.25% over 6 years The revenue of Molbio Diagnostics Ltd for the Jun '26 is ₹ 411.48 crore as compare to the Mar '26 revenue of ₹ 565.41 crore. This represent the decline of -27.22% The revenue of Syngene International Ltd for the Jun '26 is ₹ 761.3 crore as compare to the Mar '26 revenue of ₹ 1058 crore. This represent the decline of -28.09% The ebitda of Molbio Diagnostics Ltd for the Jun '26 is ₹ 103.68 crore as compare to the Mar '26 ebitda of ₹ 163.51 crore. This represent the decline of -36.59% The ebitda of Syngene International Ltd for the Jun '26 is ₹ 102.6 crore as compare to the Mar '26 ebitda of ₹ 319.6 crore. This represent the decline of -67.9% The net profit of Molbio Diagnostics Ltd changed from ₹ -23.94 crore to ₹ 52.74 crore over 5 quarters. This represents a CAGR of NaN% The net profit of Syngene International Ltd changed from ₹ 75.7 crore to ₹ -9 crore over 9 quarters. This represents a CAGR of NaN% The Dividend Payout of Molbio Diagnostics Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Syngene International Ltd changed from 10.18 % on March 2022 to 16.52 % on March 2026 . This represents a CAGR of 10.17% over 5 years .

About Molbio Diagnostics Ltd

Molbio Diagnostics Limited was originally incorporated as Molbio Diagnostics Private Limited' at Panaji, as a private company dated October 20, 2000.
Thereafter, Company was converted from a private limited company to a public limited company, and the name of Company was changed to Molbio Diagnostics Limited, and a fresh certificate of incorporation dated January 16, 2025 was issued to Company by the RoC. Company is innovative point-of-care (POC) diagnostics company focused on expanding access to accurate, rapid and cost-effective healthcare technologies to diagnose infectious and non-communicable diseases.
The Company entered into a joint venture agreement in August, 2011 with Bigtec Innovations Private Limited and Bigtec Private Limited, which started operations in 2000.
Bigtec Innovations Private Limited got merged with the Company in 2015.

About Syngene International Ltd

Syngene International Limited is an integrated research, development and manufacturing services organization serving global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors.
Headquartered in India, the operations are driven by its highly qualified teams comprising 5,778scientists and its state-of-the-art facilities, spread over 3 million sq. ft.
The Company operate into 4 business divisions comprising of Discovery Services, Translational & Clinical Research, Dedicated Centers, and Contract Development and Manufacturing Services. Syngene International Limited was incorporated at Bangalore in 1993.
The Company was promoted by Biocon and Kiran Mazumdar Shaw, a promoter of Biocon Limited.
The Company's health-related services extend across all major therapeutic areas and modalities.

FAQs for the comparison of null and Syngene International Ltd

Which company has a larger market capitalization, Molbio Diagnostics Ltd or Syngene International Ltd?

Market cap of Molbio Diagnostics Ltd is 14,262 Cr while Market cap of Syngene International Ltd is 14,810 Cr

What are the key factors driving the stock performance of Molbio Diagnostics Ltd and Syngene International Ltd?

The stock performance of Molbio Diagnostics Ltd and Syngene International Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Molbio Diagnostics Ltd and Syngene International Ltd?

As of October 25, 2026, the Molbio Diagnostics Ltd stock price is INR ₹1237.65. On the other hand, Syngene International Ltd stock price is INR ₹366.9.

How do dividend payouts of Molbio Diagnostics Ltd and Syngene International Ltd compare?

To compare the dividend payouts of Molbio Diagnostics Ltd and Syngene International Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.